SCHEMBL25866716

SCHEMBL25866716

CC(C)(C)CCNc1ccc(N)cc1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2B P18089 1/20 0.36
AR P10275 1/20 0.35
VDR P11473 1/20 0.35
NQO2 P16083 4/20 0.33
HRH4 Q9H3N8 2/20 0.32
BRAF P15056 1/20 0.31
KDR P35968 1/20 0.31
BACE1 P56817 1/20 0.31
BACE2 Q9Y5Z0 1/20 0.31
PDK1 Q15118 1/20 0.31
PDK2 Q15119 1/20 0.31
PDK3 Q15120 1/20 0.31
PDK4 Q16654 1/20 0.31
PARK7 Q99497 1/20 0.31
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
MAPT P10636 1/20 0.30
MAPK1 P28482 1/20 0.30
GFER P55789 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23797765 0.81 IDO1 (0.39) ADRA2BNQO2ALDH1A1LMNAMAPT
SCHEMBL25873234 0.81 POLB (0.44) ARVDRALDH1A1LMNAMAPT
SCHEMBL23709737 0.80 FERMT2 (0.41) ADRA2BALDH1A1LMNAMAPTMAPK1
SCHEMBL18403936 0.79 ADRA2B (0.37) ADRA2BNQO2KDRALDH1A1LMNA
SCHEMBL13718267 0.77 ADRA2B (0.38) ADRA2BKDRALDH1A1MAPK1TDP1
SCHEMBL15384343 0.77 MAPT (0.42) ADRA2BALDH1A1LMNAMAPTMAPK1
SCHEMBL9024554 0.77 NCF1 (0.44) ADRA2BNQO2ALDH1A1
SCHEMBL23798296 0.77 BACE1 (0.41) ADRA2BNQO2HRH4BACE1BACE2
SCHEMBL9024162 0.77 ADRA2B (0.36) ADRA2BNQO2ALDH1A1LMNAMAPT
SCHEMBL22174845 0.75 ADRA2B (0.35) ADRA2BNQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691972-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2023-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691972-B2 Compounds for targeted degradation of BRD9 BRD9, BRD1, BRWD1 ADRA2B 4207/4885AR 2060/4885VDR 3618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.